InVision Medical Technology
FDA-cleared echo AI that automates LVEF, flags cardiac amyloidosis, and bills under CPT 0932T plus a 2026 Medicare NTAP.
InVision is the echo AI you buy when the committee asks for peer-reviewed evidence and a billing code, not a demo. The randomized Nature trial (He et al., 2023), two FDA clearances, live CPT 0932T, and the 2026 Medicare NTAP of up to $2,275 per eligible inpatient stay make the ROI argument for you. The tradeoff is scope and speed: enterprise deployment against existing PACS, CVIS, and Epic, a four-week implementation, and a pipeline where cirrhosis, valvular work, and reporting are still in development. If your lab needs real-time inference at the acquisition console, look at scanner-native bundles from your GE, Philips, or Siemens rep instead; if you need an enterprise layer that reads the
Verified 5d ago · liveness 60/100 · cite: rightaichoice.com/tools/invision-medical-technology
- Large health systems and hospital networks standardizing echo interpretation across multiple sites
- Cardiology service line directors who need peer-reviewed evidence and a reimbursement path before signing
- Echo lab directors and sonographers dealing with measurement variability and interpretation time
- Population health teams using routine echo volume to surface underdiagnosed cardiac amyloidosis
- Independent clinics with no PACS, CVIS, or Epic environment to deploy against
- Labs that need real-time inference at the acquisition console rather than DICOM post-processing
- Multi-modality imaging departments — InVision's live products are echocardiography only
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip InVision if you need real-time AI inference at the acquisition console or coverage beyond echocardiography — the cleared products are DICOM post-processing for LVEF and cardiac amyloidosis, with cirrhosis, reporting, and valvular work still in development.
On-premise deployment means you carry the compute, storage, and IT maintenance yourself — budget for the hardware and staff time, not just the license.
InVision is priced for enterprise imaging budgets — health systems with an existing PACS, CVIS, and Epic footprint — and sold as a clinical program rather than a per-seat tool. The economics hinge on offsetting cost against CPT 0932T payments in outpatient heart failure subtype classification and, from October 1, 2026, a Medicare NTAP of up to $2,275 per eligible inpatient stay. Compare it against scanner-native AI bundles from your GE, Philips, or Siemens rep, which arrive bundled into
In short
InVision Medical Technology — FDA-cleared echo AI that automates LVEF, flags cardiac amyloidosis, and bills under CPT 0932T plus a 2026 Medicare NTAP. Best for Large health systems and hospital networks standardizing echo interpretation across multiple sites, Cardiology service line directors who need peer-reviewed evidence and a reimbursement path before signing, Echo lab directors and sonographers dealing with measurement variability and interpretation time. Contact Sales pricing.
Viability Score
How well maintained and how widely used is InVision Medical Technology? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this
Last calculated: October 2026
How we score →Key Features
- Precision LVEF: automated left ventricular ejection fraction from standard echo DICOM
- Precision LVEF reported 4.1% mean absolute error predicting EF in external validation
- Blinded randomized trial (Nature, He et al. 2023) across 3,495 transthoracic echocardiograms
- 16.8% of AI studies substantially changed by cardiologists vs 27.2% for sonographers
- Precision Cardiac Amyloid: detection from apical-4-chamber and parasternal-long-axis views
- Developed with Alexion, AstraZeneca Rare Disease
- FDA 510(k) clearance for Precision LVEF and Precision Cardiac Amyloid
- Precision Cardiac Amyloid holds FDA Breakthrough Device designation and TAP enrollment
- Vendor-neutral DICOM input from GE, Philips, Siemens, Canon, and handheld POCUS
- DICOM-native post-processing; runs alongside PACS, CVIS, and Epic EHR
- No new hardware, no new views, no acquisition change required
- Typical four-week implementation from kick-off to go-live
- On-premise or validated cloud deployment with PHI staying in your network on-premise
- US-only data residency; SOC 2, ISO 13485, and HIPAA aligned
- Precision Reporting (in development): 18 B-mode and Doppler parameters with draft wording on EchoPrime and EchoNet-Measurements
About InVision Medical Technology
InVision Medical Technology sells FDA-cleared echocardiography AI to hospital systems, not to individual readers. Two algorithms are live. Precision LVEF automates left ventricular ejection fraction and chamber metrics from the standard echo DICOM your lab already produces; the model builds on EchoNet-Dynamic research first published in Nature in 2020 and reports a 4.1% mean absolute error predicting ejection fraction in external validation. Precision Cardiac Amyloid flags cardiac amyloidosis from apical-4-chamber and parasternal-long-axis views, was developed with Alexion, AstraZeneca Rare Disease, and holds Breakthrough Device designation plus FDA TAP enrollment. Both hold 510(k) clearance. The evidence is unusual for imaging AI: a blinded, randomized prospective trial published in Nature (He et al., 2023) across 3,495 transthoracic echocardiograms, in which cardiologists substantially changed 16.8% of AI studies versus 27.2% of sonographer studies. The commercial case is reimbursement. CPT Category III code 0932T has been live since January 1, 2025 for adjunctive AI analysis supporting heart failure subtype classification, with Precision Cardiac Amyloid in scope when LVEF is 50% or above and Precision LVEF establishing that threshold in the same pass. On the inpatient side, CMS granted a Medicare New Technology Add-on Payment of up to $2,275 per eligible stay on top of the MS-DRG, effective October 1, 2026. Deployment is deliberately unglamorous: vendor-neutral DICOM in from GE, Philips, Siemens, Canon, and handheld POCUS, running alongside existing PACS, CVIS, and Epic EHR, with no new hardware, no new views, and a typical four-week kick-off-to-go-live. You choose on-premise or the vendor's validated cloud, with PHI staying inside your network on-premise and customer data US-only either way. The pipeline is where service-line expansion lives: Precision Reporting automates structured echo reports with 18 B-mode and Doppler parameters and draft wording on EchoPrime and EchoNet-Measurements, Precision Cirrhosis reads the subcostal view for liver disease, and Precision VHD extends to mitral, tricuspid, and aortic. Against scanner-native AI bundles and self-serve echo tools, InVision trades breadth and speed for regulatory clearance, randomized trial evidence, and a billing code.
Behind the Verdict
InVision's pitch is narrow and defensible: it does two things on echo, both cleared, one of them backed by the only blinded randomized prospective trial run in AI cardiology. Precision LVEF automates ejection fraction and chamber metrics from standard DICOM post-processing, reporting 4.1% mean absolute error in external validation and a 16.8% vs 27.2% substantial-correction rate for AI versus sonographer initial reads in the Nature trial. Precision Cardiac Amyloid screens apical-4-chamber and parasternal-long-axis views for a disease that is routinely missed and now treatable, developed with Alexion, AstraZeneca Rare Disease, and carrying Breakthrough Device designation plus TAP enrollment. For a service line director, those are the two artifacts a committee actually reads. Strengths: the reimbursement story is unusually concrete for imaging AI. CPT 0932T has been payable since January 1, 2025 for adjunctive AI analysis supporting heart failure subtype classification, and the CMS New Technology Add-on Payment of up to $2,275 per eligible inpatient stay lands October 1, 2026 on top of the MS-DRG. Vendor-neutral DICOM input means no scanner swap and no new acquisition protocol, and either on-premise or the validated cloud keeps PHI inside your network, with US-only data residency and SOC 2, ISO 13485, and HIPAA alignment. Four weeks from kick-off to go-live is short for enterprise imaging software. Weaknesses are scope and integration posture. This is echocardiography only; there is no CT, MR, or nuclear product. Inference is post-processing on DICOM rather than real-time analysis at the acquisition console, so sonographers do not get feedback mid-scan. Deployment assumes PACS, CVIS, and Epic already exist, which rules out small independent clinics, and the product is sold to health systems rather than to individual readers. The pipeline — Precision Cirrhosis (Breakthrough Device designation), Precision Reporting on EchoPrime and EchoNet-Measurements, and Precision VHD for mitral, tricuspid, and aortic — is not live today, so buy the two cleared algorithms you can use now, not the roadmap. Where it fits: multi-site health systems standardizing echo measurement and running population-health screening across existing echo volume, and core labs or CROs that need cleared, regulatory-grade algorithms. Where it doesn't: single-modality boutique labs wanting scanner-embedded inference, or anyone expecting general-purpose imaging AI across modalities from one vendor.
Researching InVision Medical Technology? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas InVision Medical Technology actually fits — and what changes day-one when you adopt it.
Route routine transthoracic echo DICOM through InVision as a post-processing step before reads are finalized, so every study carries an automated EF and chamber metrics.
Outcome: Sonographers start reads from a measured EF and cardiologists correct far fewer studies than they did from sonographer-only initial assessments — 16.8% versus 27.2% substantial correction in the published randomized trial.
Bring the Nature 2023 randomized trial, two FDA 510(k) clearances, live CPT 0932T, and the October 1, 2026 NTAP into the capital request alongside a four-week deployment plan.
Outcome: The committee reviews a cleared product with a published randomized trial and a named billing code instead of a pilot proposal, shortening the approval path.
Enable Precision Cardiac Amyloid on apical-4-chamber and parasternal-long-axis views so every routine echo is screened for cardiac amyloidosis at no added clinician workload.
Outcome: Rare, treatable, routinely missed cases get flagged from imaging volume the system already produces, and Precision LVEF sets the LVEF ≥ 50% threshold that puts the study in scope for CPT 0932T.
Use Cases
- Automate LVEF measurement in routine echo studies to cut sonographer and cardiologist effort and improve measurement consistency.
- Screen every routine echo for cardiac amyloidosis without adding clinician workload, catching a disease that is routinely missed.
- Standardize echo measurements across a multi-site health system to reduce inter-operator variability and support quality programs.
- Run AI post-processing on existing DICOM studies to surface undiagnosed heart failure and cardiomyopathy.
- Bill adjunctive AI analysis under CPT 0932T in heart failure subtype classification workflows, with Precision LVEF establishing the LVEF ≥ 50% threshold in the same pass.
- Capture Medicare NTAP up to $2,275 per eligible inpatient stay on top of the MS-DRG from October 1, 2026.
- Deploy FDA-cleared AI into an enterprise PACS/EHR workflow to support the cardiology service line.
Models Under the Hood
as of 2026-09-23
Limitations
- InVision's live product scope is echocardiography: Precision LVEF and Precision Cardiac Amyloid.
- Precision Cirrhosis, Precision Reporting, and Precision VHD are in development, not shipping today.
- Inference is DICOM-native post-processing, so there is no real-time, scanner-integrated analysis at the acquisition console; the workflow assumes existing PACS, CVIS, and Epic integration, which rules out clinics without that infrastructure.
- Deployment is enterprise-scale, with a typical four-week implementation from kick-off to go-live.
- Customer data must stay in the United States, so non-US sites are out of scope.
- The published evidence covers LVEF measurement consistency and time savings; it does not extend to general-purpose or multi-modality AI claims.
as of 2026-10-03
Verification history
We have re-verified InVision Medical Technology 6 times since . Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-checked, vendor evidence unchanged
- — re-checked, vendor evidence unchanged
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Free to cite with attribution — this page re-verifies continuously.
Where the pricing makes sense
The company stage and team size where InVision Medical Technology's pricing actually pencils out — and where peers do it cheaper.
InVision is priced for enterprise imaging budgets — health systems with an existing PACS, CVIS, and Epic footprint — and sold as a clinical program rather than a per-seat tool. The economics hinge on offsetting cost against CPT 0932T payments in outpatient heart failure subtype classification and, from October 1, 2026, a Medicare NTAP of up to $2,275 per eligible inpatient stay. Compare it against scanner-native AI bundles from your GE, Philips, or Siemens rep, which arrive bundled into
Setup time & first value
How long it actually takes to get something useful out of InVision Medical Technology — broken out by persona, not the marketing-page minute.
Plan about four weeks from kick-off to go-live, the vendor's stated typical timeline for deploying against your existing PACS, CVIS, and Epic EHR with no new hardware and no acquisition change. Echo lab directors and sonographers see automated LVEF output as soon as DICOM routing is validated; service line directors needing a capital committee package should add time on their own side for
Switching to or from InVision Medical Technology
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
- →From manual sonographer EF measurement: add InVision as DICOM post-processing beside existing reads, with no scanner or protocol change.
- →From scanner-native AI bundles: move analysis off the acquisition console to a vendor-neutral layer that reads GE, Philips, Siemens, Canon, and handheld POCUS DICOM alike.
- →From a homegrown or academic EF model: replace with FDA 510(k)-cleared Precision LVEF carrying prospective randomized trial evidence.
- →From no amyloid screening program: turn on Precision Cardiac Amyloid over apical-4-chamber and parasternal-long-axis views already in your archive.
- ↗To a scanner-native AI bundle: expect to lose vendor-neutral DICOM coverage across GE, Philips, Siemens, Canon, and handheld POCUS in exchange for console-integrated inference.
- ↗To an in-house research model: you would give up FDA 510(k) clearance, the randomized trial evidence, and any current or future reimbursement under CPT 0932T.
- ↗To a multi-modality imaging AI suite: you would trade echo-specific depth (LVEF plus amyloid) for broader modality coverage outside echocardiography.
Integrations
Resources & Guides
- Resourceinvisionmedtech.com
Deployment · InVision Medical Technology
Helpful link from invisionmedtech.com
- Resourceinvisionmedtech.com
Reimbursement · InVision Medical Technology
Helpful link from invisionmedtech.com
- Resourceinvisionmedtech.com
Blog · InVision Medical Technology
Helpful link from invisionmedtech.com
Tutorials & Learning
YouTube returned 6 videos for “InVision Medical Technology”, and we withheld 6: 6 did not mention InVision Medical Technology. We are showing none, because we could not prove any of them are about InVision Medical Technology.
Official links
Tools that pair well with InVision Medical Technology
Common stack mates teams adopt alongside InVision Medical Technology, with the specific reason each pairing earns its keep.
Paige AI
FDA-cleared AI for cancer pathology: prostate, breast, GI and pan-cancer detection on H&E slides, plus Virchow foundation models for research.
Quibim
Cloud-based medical imaging platform that turns MRI, CT, and PET scans into regulatory-cleared quantitative imaging biomarkers.
Flatiron Health
Oncology real-world evidence platform turning patient data into AI-assisted cancer research insights.
Featured Head-to-Head Comparisons
Invision Medical Technology vs Isomorphic Labs
InVision Medical Technology and Isomorphic Labs serve entirely different markets. InVision provides clinically deployed, FDA-cleared AI that reduces sonographer workload and detects cardiac amyloidosis in existing echo workflows, with clear reimbursement. Isomorphic Labs is a research-stage drug discovery AI that partners only with large pharma. For a health system seeking immediate ROI through regulatory-approved AI with CPT billing, InVision is the clear choice. Isomorphic Labs is irrelevant for clinical imaging operations.
Invision Medical Technology vs Rapidsos
These are not competitors. InVision Medical Technology is FDA-cleared AI that automates LVEF and amyloid detection inside hospital echo workflows — sold to cardiology labs with PACS/CVIS/Epic infrastructure. RapidSOS is the data layer that pipes device telematics, live video, and AI transcription into 911 dispatch centers and enterprise safety programs. A hospital echo lab buying InVision would never shortlist RapidSOS, and a 911 ECC evaluating RapidSOS is not in the market for echo AI. If you arrived here looking for a head-to-head, you are comparing the wrong pair — treat each on its own terms.
Invision Medical Technology vs Codametrix
InVision Medical Technology and CodaMetrix serve entirely different clinical and operational domains. InVision is a specialized AI for echocardiography, FDA-cleared with CPT reimbursement, ideal for cardiology departments focused on diagnostic precision and amyloid screening. CodaMetrix is a broad enterprise coding platform with proven ROI for large health systems tackling denial management and staff productivity. The choice depends on whether the buyer's priority is clinical decision support (InVision) or revenue cycle automation (CodaMetrix).
Alternatives to InVision Medical Technology
View allPaige AI
FDA-cleared AI for cancer pathology: prostate, breast, GI and pan-cancer detection on H&E slides, plus Virchow foundation models for research.
Quibim
Cloud-based medical imaging platform that turns MRI, CT, and PET scans into regulatory-cleared quantitative imaging biomarkers.
Flatiron Health
Oncology real-world evidence platform turning patient data into AI-assisted cancer research insights.
Frequently Asked Questions
Categories
Used InVision Medical Technology? Help shape our editorial sentiment research.